Skip to main content
EOLS
NASDAQ Life Sciences

Evolus Reports Q4 EPS of $0, Projects FY Sales of $327M-$337M

feedReported by Reuters
Sentiment info
Neutral
Importance info
7
Price
$4.45
Mkt Cap
$267.706M
52W Low
$4.091
52W High
$14.94
Market data snapshot near publication time

summarizeSummary

Evolus, Inc. announced its fourth-quarter results, reporting earnings per share of $0 and a net income of $130 thousand on product revenue of $89.216 million. The company also provided full-year sales guidance for $327 million to $337 million. This is a critical update for investors as quarterly earnings and forward guidance significantly influence valuation and future expectations. Traders will be assessing these figures against analyst consensus to determine the immediate market reaction and adjust positions accordingly. The low net income and $0 EPS indicate minimal profitability for the quarter.

At the time of this announcement, EOLS was trading at $4.45 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $267.7M. The 52-week trading range was $4.09 to $14.94. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.


show_chartPrice Chart

Share this article

Copied!

feed EOLS - Latest Insights

EOLS
Mar 03, 2026, 5:01 PM EST
Filing Type: 10-K
Importance Score:
7
EOLS
Mar 03, 2026, 4:21 PM EST
Source: Dow Jones Newswires
Importance Score:
7
EOLS
Mar 03, 2026, 4:05 PM EST
Source: Reuters
Importance Score:
7
EOLS
Jan 09, 2026, 8:34 AM EST
Filing Type: 8-K
Importance Score:
8